Cargando…
Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats
Prostacyclin receptor (IP) and peroxisome proliferator-activated receptor-gamma (PPARγ) are both potential targets for treatment of pulmonary arterial hypertension (PAH). Expression of IP and PPARγ decreases in PAH, suggesting that screening of dual agonists of IP and PPARγ might be an efficient met...
Autores principales: | Xia, Jingwen, Yang, Li, Dong, Liang, Niu, Mengjie, Zhang, Shengli, Yang, Zhiwei, Wumaier, Gulinuer, Li, Ying, Wei, Xiaomin, Gong, Yi, Zhu, Ning, Li, Shengqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829529/ https://www.ncbi.nlm.nih.gov/pubmed/29527168 http://dx.doi.org/10.3389/fphar.2018.00134 |
Ejemplares similares
-
Computational identification of potential chemoprophylactic agents according to dynamic behavior of peroxisome proliferator-activated receptor gamma
por: Yang, Zhiwei, et al.
Publicado: (2020) -
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015) -
NDRG1 promotes endothelial dysfunction and hypoxia-induced pulmonary hypertension by targeting TAF15
por: Li, Chengwei, et al.
Publicado: (2023) -
Effects of Peroxisome Proliferator-Activated Receptor-Gamma Agonists on Cognitive Function: A Systematic Review and Meta-Analysis
por: Zhong, Hongfei, et al.
Publicado: (2023) -
Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report
por: Wu, Shuling, et al.
Publicado: (2022)